Arctic Bioscience (ABS) Q1 2026 TU earnings summary

Executive summary

• Achieved 78% year-over-year sales revenue growth in Q1 2026, reaching NOK 11.9 million, marking the highest first-quarter revenues to date, driven by Nutra segment performance and robust order intake.

• Launched new consumer brands in Singapore and plan to expand into Korea and Taiwan with 42 related brands, alongside B2B and concept store initiatives.

• Opened a ROMEGA® concept store in Hainan, China, and expanded B2C and B2B Nutra sales across Europe, Americas, and APAC.

• Secured NOK 15 million in new long-term financing to support operations and strengthen liquidity.

• Engaged in positive partnership discussions for HRO350, with significant clinical progress and next steps aligned following BIO Europe.

Financial highlights

• Q1 2026 sales revenue reached NOK 11.9 million, up from NOK 6.7 million in Q1 2025.

• Gross margin improved to 34.3% from 27.0% year-over-year.

• Adjusted EBITDA loss narrowed to NOK -6.5 million from NOK -9.1 million in Q1 2025.

• Available liquidity at period end was NOK 0.3 million, with NOK 15 million financing secured post-quarter.

• Salaries and operating expenses reduced by NOK 1.2 million year-over-year.

Outlook and guidance

• Strong order outlook for 2026 indicates continued Nutra revenue growth, supported by Q1 sales and order pipeline.

• Multiple new partner product launches anticipated in various regions throughout 2026.

• Further HRO350 development to be funded through partnerships or project-specific funding.

• Ongoing cost and liquidity discipline, with board monitoring additional measures.

• Data from HeROPA trial to be published and presented in 2026, increasing visibility.